SCHEMBL31662369

SCHEMBL31662369

COc1nccc2nc(OC[C@@]34CCCN3C[C@H](F)C4)nc(OCC[Si](C)(C)C)c12

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 20/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31662293 0.85 KRAS (0.42) KRAS
SCHEMBL31662256 0.85 KRAS (0.42) KRAS
SCHEMBL31662255 0.85 KRAS (0.42) KRAS
SCHEMBL30704113 0.81 KRAS (0.44) KRAS
SCHEMBL31662314 0.76 KRAS (0.45) KRAS
SCHEMBL30699434 0.73 KRAS (0.45) KRAS
SCHEMBL30597754 0.72 KRAS (0.47) KRAS
SCHEMBL31380696 0.72 KRAS (0.42) KRAS
SCHEMBL30391732 0.71 KRAS (0.47) KRAS
SCHEMBL30391087 0.71 KRAS (0.47) KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151594-A1 FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-07-17 — — WO disclosed
Send feedback